The ACCESS trial, sponsored by Universitätsklinikum Hamburg-Eppendorf, investigates the effectiveness of Assertive Community Treatment (ACT) as part of integrated care compared to standard care in patients with schizophrenia spectrum disorders treated with quetiapine IR. Given the rising prevalence of schizophrenia and the need for effective treatment strategies, this study addresses a significant market opportunity. The findings could enhance the positioning of quetiapine IR in the competitive landscape, particularly against other antipsychotics and integrated care models. The results may also inform payers and healthcare providers regarding cost-effectiveness, potentially influencing reimbursement strategies and market access.